Olistico Wealth LLC Sells 4,468 Shares of Novo Nordisk A/S (NYSE:NVO)

Olistico Wealth LLC decreased its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 57.8% in the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 3,263 shares of the company’s stock after selling 4,468 shares during the period. Olistico Wealth LLC’s holdings in Novo Nordisk A/S were worth $281,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in NVO. Strategic Investment Solutions Inc. IL bought a new position in Novo Nordisk A/S during the second quarter worth about $25,000. Daiwa Securities Group Inc. bought a new position in Novo Nordisk A/S during the 3rd quarter worth about $28,000. Capital Performance Advisors LLP bought a new stake in shares of Novo Nordisk A/S in the third quarter valued at about $42,000. Carolina Wealth Advisors LLC acquired a new position in shares of Novo Nordisk A/S during the third quarter worth about $48,000. Finally, M&R Capital Management Inc. grew its holdings in shares of Novo Nordisk A/S by 260.5% during the third quarter. M&R Capital Management Inc. now owns 411 shares of the company’s stock worth $49,000 after buying an additional 297 shares in the last quarter. Institutional investors own 11.54% of the company’s stock.

Wall Street Analysts Forecast Growth

NVO has been the topic of several research reports. UBS Group upgraded Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research note on Wednesday, January 8th. Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a report on Monday, January 6th. BNP Paribas raised shares of Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. BMO Capital Markets cut their price target on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a research report on Monday, December 23rd. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $160.00 price objective on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. One equities research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Novo Nordisk A/S has an average rating of “Buy” and an average price target of $140.20.

Novo Nordisk A/S Price Performance

Shares of NYSE NVO opened at $80.59 on Thursday. Novo Nordisk A/S has a twelve month low of $78.17 and a twelve month high of $148.15. The company has a market cap of $361.65 billion, a PE ratio of 26.08, a price-to-earnings-growth ratio of 0.89 and a beta of 0.45. The business’s 50 day moving average price is $96.63 and its two-hundred day moving average price is $116.04. The company has a quick ratio of 0.75, a current ratio of 0.94 and a debt-to-equity ratio of 0.43.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.